MedTrace Logo

Consequences of Nocturnal and Daytime Hypoxemia in COPD

NCT00547456 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-16

Study results available
· View outcomes & findings →

Summary

We will determine whether oxygen therapy lowers the level of substances in the blood which cause inflammation, which is one of the adverse effects of COPD and whether oxygen improves overall well being and quality of life as well as sleep quality.

Conditions

Interventions

DRUG

Oxygen

Oxygen 2-3L Nasal cannula

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Rubin Cohen, MD · Northwell Health

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547456 on ClinicalTrials.gov